ERBB2 and breast carcinoma: Using this combined activation signature, we found that tGLI1 and IL-6/IL-6R/GP130 signaling pathways were significantly enriched in HER2-enriched breast cancer (N = 96) and TNBC (N = 166) patients when compared to luminal subtypes (N = 247) (Figure 1D).